Biuonure strengthens its team with the appointment of Dr. Lucia Septien as CMO

Bionure has appointed Dr. Lucia Septién-Vélez as new chief medical officer (CMO), reinforcing the team at a turning point for the company that plans to start a phase 2 clinical study of its neuroprotectant compound BN201 early next year.

Prior to joining Bionure, Dr. Septien worked as a clinical doctor in neurology and psychiatry then held senior medical and regulatory roles with a focus on neuroscience at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen, . She later moved to the biotech sector as chief medical officer at DBV Technologies.

See the press release for more information.